These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 30085139

  • 1. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
    Lazcano-Ponce E, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Barrientos-Gutiérrez T, Prado-Galbarro J, Stanley M, Muñoz N, Herrero R, Hernández-Ávila M.
    J Infect Dis; 2019 Jan 01; 219(1):41-49. PubMed ID: 30085139
    [Abstract] [Full Text] [Related]

  • 2. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2015 Jan 01; 11(3):732-8. PubMed ID: 25714044
    [Abstract] [Full Text] [Related]

  • 3. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, De Muynck B, De Simoni S, Suryakiran P, Hezareh M, Folschweiller N, Thomas F, Struyf F.
    Hum Vaccin Immunother; 2015 Jan 01; 11(7):1689-702. PubMed ID: 26062002
    [Abstract] [Full Text] [Related]

  • 4. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, Struyf F.
    Hum Vaccin Immunother; 2016 Jan 01; 12(1):20-9. PubMed ID: 26176261
    [Abstract] [Full Text] [Related]

  • 5. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.
    Baisley K, Kemp TJ, Mugo NR, Whitworth H, Onono MA, Njoroge B, Indangasi J, Bukusi EA, Prabhu PR, Mutani P, Galloway DA, Mwanzalime D, Kapiga S, Lacey CJ, Hayes RJ, Changalucha J, Pinto LA, Barnabas RV, Watson-Jones D.
    Lancet Glob Health; 2024 Mar 01; 12(3):e491-e499. PubMed ID: 38365419
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
    Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E.
    JAMA; 2013 May 01; 309(17):1793-802. PubMed ID: 23632723
    [Abstract] [Full Text] [Related]

  • 7. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE.
    J Infect; 2015 Jul 01; 71(1):61-73. PubMed ID: 25709084
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, Tsu V, LaMontagne DS.
    JAMA; 2011 Apr 13; 305(14):1424-31. PubMed ID: 21486975
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM.
    J Infect Dis; 2013 Oct 15; 208(8):1325-34. PubMed ID: 23901077
    [Abstract] [Full Text] [Related]

  • 10. The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules.
    Lazcano-Ponce E, Carnalla-Cortés M, Barrientos-Gutiérrez T, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Hernández-Ávila M.
    Salud Publica Mex; 2018 Oct 15; 60(6):666-673. PubMed ID: 30699272
    [Abstract] [Full Text] [Related]

  • 11. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.
    Vaccine; 2007 Jun 21; 25(26):4931-9. PubMed ID: 17499406
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
    Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli UR, Jivarajani P, Verma Y, Zomawia E, Siddiqi M, Shastri SS, Jayant K, Malvi SG, Lucas E, Michel A, Butt J, Vijayamma JM, Sankaran S, Kannan TP, Varghese R, Divate U, Thomas S, Joshi G, Willhauck-Fleckenstein M, Waterboer T, Müller M, Sehr P, Hingmire S, Kriplani A, Mishra G, Pimple S, Jadhav R, Sauvaget C, Tommasino M, Pillai MR, Indian HPV Vaccine Study Group.
    Lancet Oncol; 2016 Jan 21; 17(1):67-77. PubMed ID: 26652797
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.
    Hernández-Ávila M, Torres-Ibarra L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N, Herrero R, Villaseñor-Ruíz IF, Lazcano-Ponce E.
    Hum Vaccin Immunother; 2016 Jan 21; 12(1):30-8. PubMed ID: 26211489
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2014 Jan 21; 10(8):2438-45. PubMed ID: 25424952
    [Abstract] [Full Text] [Related]

  • 15. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER.
    Hum Vaccin Immunother; 2019 Jan 21; 15(7-8):1980-1985. PubMed ID: 31017850
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.
    Vaccine; 2018 Nov 12; 36(46):7017-7024. PubMed ID: 30314913
    [Abstract] [Full Text] [Related]

  • 17. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, Frenette L, Giaquinto C, McNeil S, Rheault P, Durando P, Horn M, Klar M, Poncelet S, De Simoni S, Friel D, De Muynck B, Suryakiran PV, Hezareh M, Descamps D, Thomas F, Struyf F.
    J Infect Dis; 2016 Aug 15; 214(4):525-36. PubMed ID: 26908726
    [Abstract] [Full Text] [Related]

  • 18. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
    D'Addario M, Redmond S, Scott P, Egli-Gany D, Riveros-Balta AX, Henao Restrepo AM, Low N.
    Vaccine; 2017 May 19; 35(22):2892-2901. PubMed ID: 28455170
    [Abstract] [Full Text] [Related]

  • 19. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
    Lin L, Macias Parra M, Sierra VY, Salas Cespedes A, Granados MA, Luque A, Karkada N, Castrejon Alba MM, Romano-Mazzotti L, Borys D, Struyf F.
    Pediatr Infect Dis J; 2019 Oct 19; 38(10):1061-1067. PubMed ID: 31469776
    [Abstract] [Full Text] [Related]

  • 20. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
    Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli URR, Verma Y, Zomawia E, Pimple S, Tommasino M, Pawlita M, Gheit T, Waterboer T, Sehr P, Pillai MR, Indian HPV vaccine study group.
    Vaccine; 2018 Aug 06; 36(32 Pt A):4783-4791. PubMed ID: 29551226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.